Abstract:Background: Current hypertension guidelines recommend combination of an angiotensin-converting enzyme inhibitor or angiotensin-receptor blocker with a calcium-channel blocker or thiazide diuretic as initial antihypertensive therapy in patients with monotherapy uncontrolled hypertension. However, to what extent these two different combinations are comparable in blood pressure (BP)-lowering efficacy and safety remains under investigation, especially in the Chinese population. We investigated the BP-lowering efficacy and safety of the amlodipine/benazepril and benazepril/hydrochlorothiazide dual therapies in Chinese patients. Methods: In a multi-center, randomized, actively controlled, parallel-group trial, we enrolled patients with stage 1 or 2 hypertension from July 2018 to June 2021 in 20 hospitals and community health centers across China. Of the 894 screened patients, 560 eligible patients were randomly assigned to amlodipine/benazepril 5/10 mg (n = 282) or benazepril/hydrochlorothiazide 10/12.5 mg (n = 278), with 213 and 212 patients, respectively, who completed the study and had a valid repeat ambulatory BP recording during follow-up and were included in the efficacy analysis. The primary outcome was the change from baseline to 24 weeks of treatment in 24-h ambulatory systolic BP. Adverse events including symptoms and clinically significant changes in physical examinations and laboratory findings were recorded for safety analysis. Results: In the efficacy analysis (n = 425), the primary outcome, 24-h ambulatory systolic BP reduction, was - 13.8 ± 1.2 mmHg in the amlodipine/benazepril group and - 12.3 ± 1.2 mmHg in the benazepril/hydrochlorothiazide group, with a between-group difference of - 1.51 (p = 0.36) mmHg. The between-group differences for major secondary outcomes were - 1.47 (p = 0.18) in 24-h diastolic BP, - 2.86 (p = 0.13) and - 2.74 (p = 0.03) in daytime systolic and diastolic BP, and - 0.45 (p = 0.82) and - 0.93 (p = 0.44) in nighttime systolic and diastolic BP. In the safety analysis (n = 560), the incidence rate of dry cough was significantly lower in the amlodipine/benazepril group than in the benazepril/hydrochlorothiazide group (5.3% vs 10.1%, p = 0.04). Conclusions: The amlodipine/benazepril and benazepril/hydrochlorothiazide dual therapies were comparable in ambulatory systolic BP lowering. The former combination, compared with the latter, had a greater BP-lowering effect in the daytime and a lower incidence rate of dry cough. Trial registration: ClinicalTrials.gov, NCT03682692. Registered on 18 September 2018.

Multicenter Clinical Trial on Benidipine in the Treatment of Stable Angina Pectoris

Multicenter clinical trial on benidipine in the treatment of hypertension

Double-Blind, Multicenter, Active-Controlled, Randomized Clinical Trial to Assess the Safety and Efficacy of Orally Administered Nicorandil in Patients with Stable Angina Pectoris in China

Efficacy of Different Doses of Nitroglycerin Combined with Clopidogrel in the Treatment of Angina Pectoris

Study of the Anti-Hypertensive Efficacy and Safety of Benidipine in Patients with Essential Hypertension

Long-action antihypertensive efficacy of Benidipine in patients with mild to moderate hypertension:an open-label,ambulatory blood pressure monitoring and long-term study

The Combination of Perindopril and Indapamide in Treatment of Essential Hypertension

Double-blind Double-Dummy Randomized Controlled Multicenter Clinical Trial of Domestic Cilnidipine on Treatment of Essential Hypertension

Randomized, double-blind, parallel controlled,multicentre clinical trial of fixed combination of nitrendipine and atenolol in the treatment of mild to moderate essential hypertension

[Efficacy and safety of low dose sublingual nifedipine dripping pills (5 mg) in the acute treatment of moderate and severe hypertension: a randomized, double-blind, positive-drug parallel-controlled, multi-center clinical study]

[PP.02.03] EFFICACY AND TOLERABILITY OF NIFEDIPINE GASTROINTESTINAL THERAPEUTIC SYTEM 60MG IN CHINESE PATIENTS WITH UNCONTROLLED HYPERTENSION

Efficacy of add-on Danhong injection in patients with unstable angina pectoris: A double-blind, randomized, placebo-controlled, multicenter clinical trial

Comparison of two single-pill dual combination antihypertensive therapies in Chinese patients: a randomized, controlled trial

Effect of nifedipine controlled released tablet and atorvastatin on carotid intimamedia thickness and vascular endothelial function in patients with hypertension

Effects of Trimetazidine on Ventricular Remodeling in Coronary Artery Disease Patients with Left Ventricular Hypertrophy: the Rationale and Design of a Randomized Controlled Trial.

Comparative Bioequivalence and Food Effect of Two Formulations of 30‐mg Nifedipine Controlled‐Release Tablets in Healthy Chinese Adults

A clinical trial for evaluating efficacy and safety of amlodipine besylate/atorvastatin calcium in treating hypertension complicated with hyperlipidemia

Efficacy of INtensive Treatment vs. Standard Treatment of COmpound DanshEn Dripping Pills in Refractory Angina Patients With Incomplete Revascularization (INCODER Study): Study Protocol for a Multicenter, Double-Blind, Randomized Controlled, Superiority Trial

Clinical investigation of the efficacy and safety of continuous intravenous Diltiazem for patients with refractory angina pectoris

A meta-analysis of anti-hypertensive efficacy and safety between cilnidipine and amlodipine

Efficacy and safety of nifedipine GITS in Chinese patients with hypertension--a post-marketing surveillance study.